黃斑部病變治療市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、疾病階段、治療類型、銷售管道、地區和競爭格局分類（2020-2030 年預測）

全球黃斑部病變治療市場將從2024年的141.9億美元成長到2030年的229億美元，複合年成長率為8.30%。黃斑部病變治療涵蓋一系列藥物干預措施，主要包括抗血管內皮生長因子（抗VEGF）藥物，以及其他旨在控制老年黃斑部病變（AMD）的輔助療法。 AMD是一種進行性眼科疾病，會導致中心視力喪失。

主要市場促進因素

全球黃斑部病變治療市場主要受到老年黃斑部病變（AMD）在全球範圍內日益成長的患病率以及治療方法和藥物研發的不斷進步的顯著推動。 AMD發病率的上升導致患者群體不斷擴大，對有效干預措施的需求也隨之成長。

主要市場挑戰

長期治療方案帶來的巨大經濟負擔，尤其是反覆進行玻璃體內注射抗血管內皮生長因子（抗VEGF）藥物，直接阻礙了全球黃斑部病變治療市場的成長。這種經濟壓力構成了一大障礙，限制了患者獲得必要治療的機會，並給各個地區的醫療保健預算帶來了相當大的壓力。

主要市場趨勢

針對乾性老年黃斑部病變（AMD）的補體系統抑制劑的研發代表著一個顯著的成長趨勢，滿足了巨大的未被滿足的醫療需求。地圖狀萎縮是乾性AMD的一種晚期形式，先前一直缺乏核准的疾病改善療法。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球黃斑部病變治療市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依類型（乾性老年黃斑部病變、濕性老年黃斑部病變）
  • 依疾病階段分類（早期AMD、中期AMD、晚期AMD）
  • 依治療類型（藥物、器械、手術）
  • 依銷售管道（門診手術中心、醫院、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美黃斑部病變治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲黃斑部病變治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區黃斑部病變治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲黃斑部病變治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲黃斑部病變治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球黃斑部病變治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• PanOptica Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Aerie Pharmaceutical Inc.
• REGENXBIO Inc.
• Bayer AG
• Lineage Cell Therapeutics Inc

第16章：策略建議

第17章調查會社について,免責事項

The Global Macular Degeneration Treatment Market will grow from USD 14.19 Billion in 2024 to USD 22.90 Billion by 2030 at a 8.30% CAGR. Macular degeneration treatments encompass a range of pharmacological interventions, primarily anti-vascular endothelial growth factor (anti-VEGF) agents, along with other supportive therapies designed to manage age-related macular degeneration (AMD), a progressive ophthalmic condition leading to central vision loss.

Key Market Drivers

The global macular degeneration treatment market is significantly propelled by the increasing worldwide prevalence of age-related macular degeneration and continuous advancements in therapeutic modalities and drug development. The rising incidence of AMD creates an expanding patient pool demanding effective interventions. For instance, according to Eye Health Central, in 2025, approximately 200 million people worldwide are living with some form of age-related macular degeneration, underscoring the vast and growing clinical need that drives market demand.

Key Market Challenges

The substantial economic burden associated with long-term treatment regimens, particularly the recurring intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents, directly hampers the growth of the global macular degeneration treatment market. This financial strain presents a significant barrier, limiting patient access to necessary therapies and placing considerable pressure on healthcare budgets across various regions. The chronic nature of age-related macular degeneration (AMD) necessitates ongoing treatment, often involving frequent injections, which accumulates substantial costs over time for individuals and health systems.

Key Market Trends

The development of complement system inhibitors for dry age-related macular degeneration (AMD) represents a significant growth trend, addressing a substantial unmet medical need. Geographic atrophy, an advanced form of dry AMD, previously lacked approved disease-modifying therapies. These novel inhibitors target specific components of the complement cascade, an immune pathway implicated in dry AMD's pathogenesis and progression. Such targeted treatments offer the potential to slow disease progression and preserve vision.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Pfizer Inc.
• PanOptica Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Aerie Pharmaceutical Inc.
• REGENXBIO Inc.
• Bayer AG
• Lineage Cell Therapeutics Inc

Report Scope:

In this report, the Global Macular Degeneration Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Macular Degeneration Treatment Market, By Type:

• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Macular Degeneration Treatment Market, By Stage of Disease:

• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

Macular Degeneration Treatment Market, By Treatment Type:

• Drug
• Devices
• Surgery

Macular Degeneration Treatment Market, By Sales Channel:

• Ambulatory Surgical Centers
• Hospitals
• Other

Macular Degeneration Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Macular Degeneration Treatment Market.

Available Customizations:

Global Macular Degeneration Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Macular Degeneration Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
  • 5.2.2. By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
  • 5.2.3. By Treatment Type (Drug, Devices, Surgery)
  • 5.2.4. By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Macular Degeneration Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Stage of Disease
  • 6.2.3. By Treatment Type
  • 6.2.4. By Sales Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Macular Degeneration Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Stage of Disease
      • 6.3.1.2.3. By Treatment Type
      • 6.3.1.2.4. By Sales Channel
  • 6.3.2. Canada Macular Degeneration Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Stage of Disease
      • 6.3.2.2.3. By Treatment Type
      • 6.3.2.2.4. By Sales Channel
  • 6.3.3. Mexico Macular Degeneration Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Stage of Disease
      • 6.3.3.2.3. By Treatment Type
      • 6.3.3.2.4. By Sales Channel

7. Europe Macular Degeneration Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Stage of Disease
  • 7.2.3. By Treatment Type
  • 7.2.4. By Sales Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Macular Degeneration Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Stage of Disease
      • 7.3.1.2.3. By Treatment Type
      • 7.3.1.2.4. By Sales Channel
  • 7.3.2. France Macular Degeneration Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Stage of Disease
      • 7.3.2.2.3. By Treatment Type
      • 7.3.2.2.4. By Sales Channel
  • 7.3.3. United Kingdom Macular Degeneration Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Stage of Disease
      • 7.3.3.2.3. By Treatment Type
      • 7.3.3.2.4. By Sales Channel
  • 7.3.4. Italy Macular Degeneration Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Stage of Disease
      • 7.3.4.2.3. By Treatment Type
      • 7.3.4.2.4. By Sales Channel
  • 7.3.5. Spain Macular Degeneration Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Stage of Disease
      • 7.3.5.2.3. By Treatment Type
      • 7.3.5.2.4. By Sales Channel

8. Asia Pacific Macular Degeneration Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Stage of Disease
  • 8.2.3. By Treatment Type
  • 8.2.4. By Sales Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Macular Degeneration Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Stage of Disease
      • 8.3.1.2.3. By Treatment Type
      • 8.3.1.2.4. By Sales Channel
  • 8.3.2. India Macular Degeneration Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Stage of Disease
      • 8.3.2.2.3. By Treatment Type
      • 8.3.2.2.4. By Sales Channel
  • 8.3.3. Japan Macular Degeneration Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Stage of Disease
      • 8.3.3.2.3. By Treatment Type
      • 8.3.3.2.4. By Sales Channel
  • 8.3.4. South Korea Macular Degeneration Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Stage of Disease
      • 8.3.4.2.3. By Treatment Type
      • 8.3.4.2.4. By Sales Channel
  • 8.3.5. Australia Macular Degeneration Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Stage of Disease
      • 8.3.5.2.3. By Treatment Type
      • 8.3.5.2.4. By Sales Channel

9. Middle East & Africa Macular Degeneration Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Stage of Disease
  • 9.2.3. By Treatment Type
  • 9.2.4. By Sales Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Macular Degeneration Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Stage of Disease
      • 9.3.1.2.3. By Treatment Type
      • 9.3.1.2.4. By Sales Channel
  • 9.3.2. UAE Macular Degeneration Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Stage of Disease
      • 9.3.2.2.3. By Treatment Type
      • 9.3.2.2.4. By Sales Channel
  • 9.3.3. South Africa Macular Degeneration Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Stage of Disease
      • 9.3.3.2.3. By Treatment Type
      • 9.3.3.2.4. By Sales Channel

10. South America Macular Degeneration Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Stage of Disease
  • 10.2.3. By Treatment Type
  • 10.2.4. By Sales Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Macular Degeneration Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Stage of Disease
      • 10.3.1.2.3. By Treatment Type
      • 10.3.1.2.4. By Sales Channel
  • 10.3.2. Colombia Macular Degeneration Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Stage of Disease
      • 10.3.2.2.3. By Treatment Type
      • 10.3.2.2.4. By Sales Channel
  • 10.3.3. Argentina Macular Degeneration Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Stage of Disease
      • 10.3.3.2.3. By Treatment Type
      • 10.3.3.2.4. By Sales Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Macular Degeneration Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Pfizer Inc.
• 15.4. PanOptica Inc.
• 15.5. Bausch Health Companies Inc.
• 15.6. Regeneron Pharmaceuticals Inc.
• 15.7. Aerie Pharmaceutical Inc.
• 15.8. REGENXBIO Inc.
• 15.9. Bayer AG
• 15.10. Lineage Cell Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer